Therapy Areas: Inflammatory Diseases
Active Biotech NeoTX announce dosing of the first patient in Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumours
29 October 2019 -

Biotechnology companies Active Biotech (STO: ACTI) and NeoTX Therapeutics Ltd (NeoTX) on Monday announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) in combination with AstraZeneca's checkpoint inhibitor IMFINZI (durvalumab) for the treatment of advanced or metastatic solid tumours.

Reportedly, this study aims to establish the maximum tolerated dose in the dose-escalation phase 1b study before advancing to a phase 2 cohort expansion study.

This open-label, multicentre, dose-finding Phase 1b trial enrols patients with previously treated advanced or metastatic tumours. Patients will be treated with a combination of naptumomab and durvalumab.

Naptumumab (naptumomab estafenatox, ANYARA,) is a tumour targeting immunotherapy that enhances the ability of the immune system to recognise and kill the tumour.

The companies added that Naptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016. NeoTX is responsible for the global development and commercialisation of naptumomab for the treatment of cancer under the license agreement.

Active Biotech is focussed on neurodegenerative/inflammatory diseases and cancer, while NeoTX is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology.

Login
Username:

Password: